Menu
Search
|

Menu

Close
X

MyoKardia Inc MYOK.OQ (NASDAQ Stock Exchange Global Select Market)

56.05 USD
+0.30 (+0.54%)
As of 8:46 PM IST
chart
Previous Close 55.75
Open 55.75
Volume 20,539
3m Avg Volume 136,764
Today’s High 57.00
Today’s Low 55.25
52 Week High 62.70
52 Week Low 13.10
Shares Outstanding (mil) 34.96
Market Capitalization (mil) 1,434.94
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
5
FY17
19
FY16
39
FY15
14
EPS (USD)
FY18
-0.497
FY17
-1.517
FY16
-0.580
FY15
-1.060
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
33.10
5.73
Price to Book (MRQ)
vs sector
10.40
5.45
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.72
LT Debt to Equity (MRQ)
vs sector
0.00
12.39
Return on Investment (TTM)
vs sector
-18.14
14.61
Return on Equity (TTM)
vs sector
-19.24
16.34

EXECUTIVE LEADERSHIP

Mark Perry
Interim Non-Executive Chairman of the Board, Lead Independent Director, Since 2016
Salary: --
Bonus: --
Tassos Gianakakos
President, Chief Executive Officer, Director, Since 2013
Salary: $459,545.00
Bonus: --
Taylor Harris
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
June Lee
Chief Operating Officer, Since 2017
Salary: --
Bonus: --
Joseph Lambing
Senior Vice President - Nonclinical and Pharmaceutical Development, Since 2014
Salary: $307,290.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

333 Allerton Ave
SOUTH SAN FRANCISCO   CA   94080-4816

Phone: +1650.7410900

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.

SPONSORED STORIES